Interview with Leigh Berryman , Chief Executive Officer, Maccine
Which previous professional experiences have led you to join Maccine? Getting my own company to go public in 2006 in Canada was a success for me; the company had grown…
Address: 10 Science Park Road 01-05 The Alpha Singapore Science Park II Singapore 117684,Singapore
Tel: +65 6622 9540
Web: http://www.maccine.com/index.php
Maccine is an established preclinical contract research organization providing innovative discovery support and regulatory safety assessment services.
Operating on a collaborative partnering model, Maccine has developed a portfolio of in vivo assays in key therapeutic areas including Neurology, Psychiatry, Metabolic Disorders, Pain & Inflammation, Oncology, Musculoskeletal Disorders and Women’s Health.
Naturalistic models, clinical biomarkers and clinical technology platforms are employed to better represent the clinical disease state. The team is supported by significant investment in high-end technology and access to a world class scientific community.
Preclinical Contract Research
Which previous professional experiences have led you to join Maccine? Getting my own company to go public in 2006 in Canada was a success for me; the company had grown…
Changi Airport Group’s Ching Kiat LIM reflects on a challenging 2020 for the airline industry, Changi’s longstanding excellence in pharmaceutical distribution, and how COVID-19 has pushed a greater embrace of…
Andrew Frye of medtech giant Baxter outlines his management strategy for the diverse APAC region, how growth was achieved in 2020 despite the drop in non-essential hospital visits and treatments…
Singapore – despite its modest USD 1.22 billion domestic market – has long been one of Asia’s leading biopharmaceutical hubs and a magnet for top talent. Multitudes of biopharma and…
Singapore’s Institute of Mental Health offers a comprehensive range of psychiatric, rehabilitative, and psychotherapy services for the country’s population. CEO Associate Professor Daniel Fung discusses their work to transform mental…
Kevin Zou highlights Novartis Oncology’s footprint and priorities in the diverse Asia-Pacific region, the challenges of introducing cutting-edge cell and gene therapies, how the company works with regulators and payers…
Medtech industry veteran Sanjay Prabhakaran outlines the footprint and strategy of women’s health specialist Hologic in the dynamic Asia-Pacific region, how it leveraged its molecular diagnostics expertise to pivot towards…
Novo Nordisk Singapore’s Praful Chakkarwar explains how he leverages his experience in a range of geographies in his current role, how COVID-19 has helped facilitate the affiliate’s digital transformation, the…
Nawal Roy of global digital health platform Holmusk which aims to establish data as a core utility to the treatment of behavioural health disorders explains the challenges of working in…
ASLAN Pharmaceuticals is a clinical-stage immunology-focused biopharmaceutical company. CEO Dr Carl Firth reveals why the company has shifted its focus from oncology to autoimmune diseases. He explains why their lead…
As the most important pharma hub in its region, and one of the most important globally, many companies look to launch new products in Singapore first before expanding to other…
Dr Choong May Ling, Mimi, CEO of Singapore’s Health Sciences Authority (HSA), one of the leading regulatory bodies in the Asia-Pacific region, outlines the impact of Singapore’s status as a…
At USD 150 billion, Asia-Pacific is home to the world’s second largest medtech market and, with a CAGR of nine percent, certainly its most dynamic. Chronic underfunding of healthcare systems…
See our Cookie Privacy Policy Here
